Compare Amphastar Pharmaceuticals Inc (AMPH) vs SoundHound AI Inc (SOUN) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

SOUN trades at $6.64, down 0.6% on the day, with a bearish technical signal driven by moving averages. The company shows strong revenue growth but significant losses, with a net income margin of -91.84% in 2026. Recent news highlights expansion in voice AI and the planned LivePerson acquisition, yet investor caution persists due to cash burn and execution risks. Analyst consensus remains bullish with a $13.00 price target, but the stock faces pressure from high valuation multiples and negative profitability metrics.

The outlook for SOUN hinges on scaling its AI platform to achieve profitability, supported by enterprise adoption and strategic deals. Investment opportunity lies in its growth trajectory and market position in voice AI, but risks include sustained losses, competitive pressures, and reliance on financing. Investors should weigh the high upside potential against substantial operational and financial risks.